Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sodium chloride + magnesium chloride + sodium acetate anhydrous + sodium gluconate + potassium chloride is a sterile, nonpyrogenic, isotonic intravenous electrolyte solution used for fluid and electrolyte replacement. Marketed under brand names including Normosol-R and Plasma-Lyte A, it is designed to approximate the principal ionic composition of normal human plasma and is used to replace acute extracellular fluid losses, including in surgery, trauma, burns, shock, and moderate blood loss. Its pharmacologic effect is not receptor-mediated; rather, it expands the extracellular fluid compartment and replenishes sodium, potassium, magnesium, chloride, acetate, and gluconate ions. Acetate and gluconate function as bicarbonate precursors that help buffer acid-base status. It is an inorganic salt combination product developed and manufactured by companies including Pfizer and Baxter for hospital intravenous use.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sodium chloride + magnesium chloride + sodium acetate anhydrous + sodium gluconate + potassium chloride.